Evaluating progress towards triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B in the Netherlands

Background. In 2014 the World Health Organisation (WHO) established validation criteria for elimination of mother-to-child transmission (EMTCT) of HIV and syphilis. Additionally, the WHO set targets to eliminate hepatitis, including hepatitis B (HBV). We evaluated to what extent the Netherlands has achieved the combined WHO criteria for EMTCT of...

Evaluating progress towards triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B in the Netherlands, 2012-2015

Background In 2014 the World Health Organisation (WHO) established validation criteria for elimination of mother-to-child transmission (EMTCT) of HIV and syphilis. Additionally, the WHO set targets to eliminate hepatitis, including hepatitis B (HBV). We evaluated to what extent the Netherlands has achieved the combined WHO criteria for EMTCT of...

Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: Prospective cohort study of a nationwide programme in the Netherlands

Objective To determine the accuracy of non-invasive fetal testing for the RHD gene in week 27 of pregnancy as part of an antenatal screening programme to restrict anti-D immunoglobulin use to women carrying a child positive for RHD. Design Prospectively monitoring of fetal RHD testing accuracy compared with serological cord blood typing on...

Foetale resus-D-typering toegevoegd aan prenatale screening op infectieziekten en erytrocytenimmunisatie[Foetal Rhesus-D typing added to antenatal screening for infectious diseases and erythrocyte immunisation]

Objective In the Netherlands, postnatal anti-Rhesus(D)-prophylaxis (anti-D) for RhD-negative pregnant women was introduced in 1969, followed by the introduction of antenatal anti-D administration in 1998. Screening for RhD and administration of anti-D has led to a reduction of the incidence of RhD alloimmunisation from 3.5% in 1969 to 0.29% in...

Prenatal Fetal DNA Testing for Predicting HDFN, FNAIT, and RhIG Candidacy

Fetal RHD typing can be safely used to target both antenatal and postnatal anti-D prophylaxis

A nation-wide fetal RHD screening programme for targeted antenatal and postnatal anti-D

In the Netherlands, since 1 July 2011, both antenatal anti-D immunoprophylaxis (1000 IU in the 30th week of gestation) and postnatal prophylaxis (1000 IU) is administered to only those women for whom a fetal RHD typing, performed in week 27 of pregnancy, predicts the presence of a D-positive child. The fetal RHD screening is part of the...

Health-related quality of life after completion of successful treatment for childhood cancer

Background: Previous studies have assessed health-related quality of life (HRQOL) during several treatment stages in children with cancer, but there is limited knowledge about HRQOL shortly after completing therapy. This study determined HRQOL of children with cancer shortly after the end of successful treatment compared with normative values....